CoBX Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CoBX Bio, Inc. - overview
Established
2024
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Based in Seoul, South Korea, and founded in 2024, CoBX Bio, Inc. operates as a company that researches and develops covalent bond inhibitors and molecular adhesive degraders that can address shortcomings of current synthetic medications, including resistance and insufficient effectiveness, by forming stronger attachments to disease-related proteins. In September 2025, CoBX Bio, Inc. raised KRW 7.
6 billion in pre-series A funding from Korea Investment Partners, Laplace Partners, Solid X, Solidus Investment, Company K Partners, KB Investment, and UTC Investment. The company was founded by the team of CEO Choi Hwan-geun, CEO Kim Nam-doo, and Vice President Son Jeong-beom. CoBX Bio’s proprietary platform, RaPIDome, integrates chemical proteomics, molecular modeling, and AI to identify drug mechanisms and resistance pathways. Key pipelines include covalent inhibitors targeting Menin (a MEN1-derived protein) and molecular adhesive degraders aimed at GSPT1, a protein linked to cancer cell survival.
These compounds are designed to offer enhanced efficacy and resistance mitigation. The company plans to use the September 2025 funds to support the development of Menin inhibitors and E3 ligase inhibitors.
Current Investors
KB Investment, Korea Investment Partners, Solidus Investment
Primary Industry
Pharmaceuticals
Sub Industries
Bioinformatics, Biopharmaceuticals, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.cobxbio.com/
Verticals
HealthTech, Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.